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Background/Objective: Molecular-based allergy diagnostics are gaining popularity in clinical practice. Our aim was
to evaluate their role in the tropics, given the inherent genetic and environmental differences.
Methods: We recruited subjects with history of atopy and collected data on demographics and atopic symptoms
using validated questionnaires. Subjects underwent a series of skin prick tests (SPT). Serum total and specific IgE
levels were measured using ImmunoCAP FEIA and ImmunoCAP ISAC®, respectively. We describe their pattern of
sensitization and agreement between test methods.
Results: A total of 135 subjects were recruited; mean ± SD age of 31.18 ± 12.72 years, 52.7% female. Allergic rhinitis
(AR) was the most prevalent clinical manifestation of atopy (70.7%), followed by atopic dermatitis (AD) (50.5%) and
asthma (26.2%). Polysensitization was seen in 51.1% of subjects by both SPT and ISAC. House dust mites (HDM)
were the dominant allergen, with sensitization in 67.8% and 62% of subjects on SPT and ISAC, respectively. A group
of subjects with monosensitization to B. tropicalis was identified. HDM sensitization was strongly associated with AR,
while AD and asthma were not associated with sensitization to any allergen. Agreement between SPT and ISAC
was mostly suboptimal. Greatest agreement was documented for the measurement of HDM sensitization with both
methods (κ = 0.64). Sensitization to the bulk of the remaining allergens in the ISAC panel was infrequent.
Conclusion: Multiplex methods should not be used as a screening tool, especially in a population with lower rates
of polysensitization and a dominant sensitizing allergen. There may be a role in adjusting the antigen spectrum in
the ISAC panel to regional differences.
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Atopy is on the rise worldwide. Globalization has re-
sulted in a steady increase in the prevalence of atopy in
Asia to approximate that of Western countries [1,2].
This trend is influenced by the emergence of new risk
factors for atopy related to urban living (such as pollu-
tion [2] and exposure to new food allergens), as well as
the loss of factors which are perceived to be protective,* Correspondence: amelia.santosa@gmail.com
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unless otherwise stated.like exposure to farming [3], endotoxins [4] and a wide
array of microbes [5]. The impact of atopy is likely to be
vastly different in tropical Asia when compared to tem-
perate Europe and US, where most studies were per-
formed. The applicability of in-vivo and in-vitro allergy
tests in tropical environments deserves closer attention.
Molecular-based allergy diagnostics are rapidly gaining
popularity in routine clinical care. With commercial avail-
ability of over 100 allergens, these offer the opportunity to
assess sensitization to multiple allergens concurrently, and
distinguish true sensitization from cross-reactivity [6]. The
ImmunoCAP Immuno-solid-phase allergen chip (ISAC)
(Thermo Fisher Scientific) is a fluorescent immunoassay
platform, where allergens are immobilized on a microarrayl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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antibodies to 112 components from 51 allergen sources
[6]. Unlike the singleplex methods, ISAC gives only a
semi-quantitative report of free, allergen specific IgE
(sIgE) levels [7].
Studies of atopic patients in Asia documented a poly-
sensitization rate of barely 30% [8,9]. House dust mites
(HDM) were found to dominate the sensitization profile
of Singapore pediatric and adult populations [10-12]. In
comparison, European cohorts of atopic patients re-
ported rates of polysensitization of up to 90% in their
subjects [13], where concurrent screening of a large
number of allergens could be advantageous [6]. The util-
ity of multiplex platforms in populations with a more
homogenous pattern of sensitization such as ours re-
quires a closer cost-benefit analysis.
Our objectives were to: a) describe the pattern of
sensitization in an atopic, symptomatic Singapore-Chinese
adult patients with bronchial asthma, rhinitis and/or
atopic dermatitis and identify possible new relevant aller-
gens, b) compare the applicability of ISAC and skin prick
test (SPT) in atopic patients and c) to evaluate the clinical
utility of the ISAC multiplex assay in Asia, when com-
pared to the traditional SPT.
Methods
Study population
Study subjects were Chinese patients seen for atopic
symptoms (asthma, rhinoconjunctivitis and/or atopic
dermatitis (AD)) at the internal medicine, allergy, derma-
tology or ENT (Ear, Nose, Throat) outpatient clinics at the
National University Hospital, Singapore, who agreed to
participate. Subjects were subjected to questionnaires,
SPT and venipuncture. Additionally, we included data of
healthy, non-atopic subjects from a locally conducted
study which had previously obtained approval from the
Institutional Review Board of the National University of
Singapore (Singapore, IRB reference NUS 10–445) [12].
These individuals did not have any symptoms of atopy.
Their demographics, SPT data and total serum IgE levels
had been collected previously. For the current study, ali-
quots of their stored sera were used for the ISAC test.
Written informed consent was obtained from all sub-
jects. The conduct of our study was approved by the local
Institutional Review Board (NHG ROAM:2011/02188).
Terminology
In this study, atopy was defined by the presence of
atopic symptoms (such as asthma, rhinitis, conjuncitivis
and/or AD) plus either a positive SPT to at least one al-
lergen and/or elevated total IgE in the presence of at
least one positive specific IgE. As the population resides
in a tropical environment we studied the presence of oc-
cult parasitic infections to rule out their influence ontotal serum IgE level through collaboration with the
Swiss Tropical and Public Health Institute (Socinstrasse
57, P.O. Box, 4002 Basel, Switzerland). The presence of
anti-parasite IgG against Trichinella sp, Toxocara sp,
Echinococcus granulosus, Fasciola hepatica, Schistosoma
sp, Filaria sp and Strongyloides sp was determined. Non-
atopic controls were those who had none of the above-
mentioned symptoms and had negative SPTs as well as
negative specific IgE to all tested allergens. Atopic symp-
toms were based on clinical observation and/or patients’
history. A history of asthma was defined based on the
European Community Respiratory Health Survey (ECRHS
II) [14]. Allergic rhinitis (AR) was defined according to the
Allergic Rhinitis and its Impact on Asthma (ARIA) docu-
ment [15] and AD was diagnosed based on the GA2LEN
definition [16].
Skin prick test
SPT were conducted by trained allergy nurses or physi-
cians and evaluated by a certified allergologist. All pricks
were done on the volar aspect of the subjects’ forearm
and read 15 minutes after application. We used hista-
mine (1mg/ml) as our positive control, while physio-
logical saline served as negative control (both from
Allergopharma®). The SPT was considered to be positive
if the wheal diameter was larger than 3mm. The SPT so-
lutions used in our test panel were from Allergopharma®
(A), Germany and Stallergenes® (S), France. They in-
cluded: Alternaria tenuis (A), Cladosporium herbarum
(A), Aspergillus fumigatus (A), Penicillium notatum (A),
cockroach (A), grass mix (A, containing kentucky blue
grass, meadow fescue, orchard grass, rye grass, timothy
grass and velvet grass), tree mix I (A, containing alder,
elm, hazel, poplar and willow) and II (A, containing
birch, beech, oak and plane tree), grasses/cereals (A,
containing grasses, barley, oat, rye and wheat), herbs (A,
(containing Artemisia vulgaris, Urtica dioica, Taraxacum
vulgare, Plantago lanceolata)), latex (A), Dermatopha-
goides farinae (A), Dermatophagoides pteronyssinus (A),
Dermatophagoides farinae (S), Dermatophagoides ptero-
nyssinus (S), Blomia tropicalis (S), dog (S), cat (S), prawn
(S), curry (S), coffee (S), wheat (S), soya (S) and pork
(S). HDM sensitization on SPT was measured using al-
lergen extracts from Allergopharma® and Stallergenes®
to ensure the reproducibility of HDM allergens from
different suppliers.
Serum IgE
Total serum IgE levels were measured using Phadia®
100; results were reported in kIU/L and values above 25
kIU/L were considered to be elevated. Specific IgE levels
were measured by ImmunoCAP ISAC®. Results were re-
ported in ISAC Standardized Units (ISU) and catego-
rized based on the manufacturer’s cutoff levels (<0.3
Table 1 Baseline characteristics
Subject characteristics (n=135 unless otherwise specified)
Gender (n = 131)
Male 47.3%
Female 52.7%
Age (n = 131) 31.18 ± 12.72 years






Allergic rhinitis (82/116) 70.7%
Asthma (34/130) 26.2%
Eczema (49/97) 50.5%
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ISU, moderate/high; ≥15 ISU, very high) [17]. Values
above 1 ISU were considered positive. In addition, we
measured specific IgE by ImmunoCAP to tropomyosin
(rDer p 10, Thermo Fisher Scientific) to confirm tropo-
myosin (Der p 10) results obtained by ISAC.
Statistical analysis
All the statistical analyses were performed using IBM
SPSS Statistics version 21 (SPSS Inc., Chicago, IL, USA).
Descriptive statistics were used with median, minimum
and maximum values to describe continuous variables;
absolute number and percentage were reported for cat-
egorical variables. Logistic regression was performed to
determine the association between sensitization and
atopy status. Agreement was measured between aller-
gens in the SPT and ISAC panels. Each allergenic source
on the SPT was compared against the composite of the
allergenic molecules within the ISAC panel that belong
to the corresponding allergenic source, as well as to the
individual allergenic molecules from the corresponding
allergenic source. Cohen’s kappa statistics was used as a
measure of agreement. The strength of agreement was
as follows: Kappa < 0 was poor, 0–0.2 was slight, 0.21 to
0.4 was fair, 0.41-0.6 was moderate, 0.61-0.8 was good
and 0.81-1 was excellent [18]. Statistical significance was
set at p < 0.05.
Results
ISAC was performed on 87 subjects. We report demo-
graphic and symptoms data for all recruited subjects (n =
135); statistics for analysis of agreement and association
with atopic symptoms was performed on subjects with
ISAC data (n = 87).
Of all recruited subjects, 71 (52.7%) were female with
a mean age of 31.18 ± 12.72 years. The majority of sub-
jects were born in Singapore (85.7%). AR was the most
prevalent clinical manifestation of atopy, affecting 82/
116 (70.7%) of subjects, followed by AD (49/97, 50.5%)
and asthma (34/130, 26.2%) (Table 1). The mean total
serum IgE was 133.83 ± 172.13 kIU/L (range 2–1018
kIU/L). Median total serum IgE was significantly higher
in atopics (vs non-atopics) (85.80 kIU/L vs 17.60 kIU/L,
p = 0.001), sensitized (vs non-sensitized) individuals
(186.84 kIU/L vs 55.36 kIU/L, p = 0.004), HDM sensi-
tized (vs non-HDM sensitized) individuals (193.24 kIU/L
vs 55.95 kIU/L, p =0.005) and in those with (vs without)
AR (110.50 kIU/L vs 35.20 kIU/L, p = 0.006). Levels did
not differ between subjects with/without asthma and
AD. Polysensitization was seen in 51.1% (68/134) of sub-
jects by both SPT and ISAC.
In 87 subjects with ISAC data, further analysis was
conducted. 59 (67.8%) were sensitized to HDM on SPT.
Subjects with no HDM sensitization were less likely tobe sensitized to any of the other allergens (OR (95%CI)
0.06 (0.01-0.15), p < 0.005) (data not shown). Monosensi-
tization to HDM was present in 15 (17.2%). The majority
(50.1%) had concurrent sensitization to a variety of other
allergens in addition to HDM, while 25 (28.7%) did not
have measureable sensitization to any allergen. Among
individuals with HDM sensitization, one subject each
was solely sensitized to B. tropicalis and D. farinae. Con-
current sensitization to all HDM species was seen in 49
(56.3%). In comparison, ISAC reported a lower propor-
tion of HDM sensitized individuals (n = 54, 62%), but
found that among them seven subjects (8%) had single-
species sensitization to B. tropicalis, while none were
solely sensitized to D. farinae or D. pteronyssinus. 34
(39.1%) were sensitized to all HDM species (Figure 1).
While SPT reported that HDM sensitization was most
frequently to D. farinae, ISAC found B. tropicalis to be
the dominant HDM allergen.
HDM sensitization was significantly associated with
AR on both SPT and ISAC. The odds ratio of AR in a
subject sensitized to HDM on SPT was 10.92 (95% con-
fidence interval 1.054–113.357, p = 0.044). On ISAC,
every subject with sensitization to HDM had AR (p =
0.024). Sensitization was more frequently seen against
HDM group 2 allergens. Agreement with SPT was nu-
merically better with group 2 allergens (compared to
group 1 mite allergens) (Table 2), and their association
with AR symptoms was slightly stronger (OR(95%CI)
4.82 (1.88 to 12.34), p = 0.001 for AR in subjects sensi-
tized to Der p 1 vs OR (95% CI) 8.08 (2.61 to 25.02), p <
Figure 1 HDM sensitization pattern on skin prick test and ISAC.
Table 3 Frequency of sensitization to the various
allergens included in the skin prick test (SPT) panel
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(2.08 to 13.66), p < 0.001 for AR in subjects sensitized to
Der f 1 vs OR (95% CI) 6.90 (2.43 to 19.61), p < 0.001
for Der f 2 sensitized subjects). We did not find any sig-
nificant association between sensitization to any par-
ticular allergen with asthma or AD.
The agreement between HDM SPT extracts from
Allergopharma® and Stallergenes® was good (κ = 0.76,
95% CI 0.62-0.90). The overall agreement for HDMTable 2 Agreement between skin prick test (SPT) and
ISAC for house dust mites




Der f 1 0.46 (0.30-0.63) <0.001
Der f 2 0.55 (0.39-0.71) <0.001
Der f (total) 0.63 (0.46-0.79) <0.001
Dermatophagoides
pteronyssinus
Der p 1 0.43 (0.26-0.59) <0.001
Der p 2 0.49 (0.33-0.65) <0.001
Der p 10 0.04 (−0.05-0.08) 0.186
Der p (total) 0.56 (0.40-0.73) <0.001
Blomia tropicalis Blo t 5 0.60 (0.44-0.77) < 0.001
Please refer to Additional file 1: Table S1 for the remaining allergens.sensitization between SPT and ISAC was fair (κ = 0.57,
95%CI 0.40-74, p < 0.001), where agreement was greatest
for D. farinae (κ = 0.63, 95% CI 0.46-0.79, p < 0.001). D.
pteronyssinus and B. tropicalis followed with moderate
levels of agreement (κ of 0.56 and 0.60, respectively)
(Table 2).
Sensitization to allergens other than HDM was less
frequent on both SPT and ISAC (Tables 3 and 4). The
majority of subjects had owned a pet at some point of
their lives (59.1%), most often dogs, rodents, birds and
cats. However, pet ownership was not associated with
measurable sensitization to the respective animals (both
on skin prick and ISAC), regardless of whether pet own-
ership was current (ongoing exposure) or in the past.
ISAC did not identify additional allergens which could
be locally important from the large range of allergens in-
cluded in their panel. The level of agreement between
ISAC and SPT for allergens other than HDM was slight,
or at most fair (Additional file 1: Table S1). Sensitization
to HDM tropomyosin (Der p 10) was seen in 6.7% sub-
jects by ISAC and in 5 (8.3% of 60 subjects) who had
tropomyosin measurement by ImmunoCAP. There was
moderate agreement between serum specific IgE against














Table 4 Proportion of sensitized subjects measured through the ISAC panel of 112 allergenic molecules
Allergen group Allergen Allergenic molecule Very high (%) Moderate/high (%) Low (%) Negative (%)
Egg
Egg white
Gal d 1 0 0 0 100
Gal d 2 0 0 0 100
Gal d 3 0 0 2.2 97.8
Egg yolk Gal d 5 0 0 0 100
Milk Cow’s Milk
Bos d 4 0 0 0.7 99.3
Bos d 5 0 0 0 100
Bos d 8 0 0 0 100
Bos d lactoferin 0 0 0 100
Fish Cod Gad c 1 0 0 0 100
Shrimp Shrimp
Pen m 2 0 1.5 0 98.5
Pen m 4 0 0 0 100
Nuts & seeds
Cashewnut Ana o 2 0 0 0.7 99.3
Brazil Nut Ber e 1 0 0 0 100
Hazelnut Cor a 9 0 0 0 100
Walnut
Jug r 1 0 0 0 100
Jug r 2 0 0 1.5 98.5
Sesame Ses i 1 0 0 0 100
Legume
Peanut
Ara h 1 0.7 0 0.7 98.5
Ara h 2 0 0 0 100
Ara h 3 0 0 0 100
Ara h 6 0 0 0 100
Soy
Gly m 5 0 0 0 100
Gly m 6 0 0 0.7 100
Cereals
Buckwheat Fag e 2 0 0 0 100
Wheat
Tri a 14 0 0 0 100
Tri a 19.0101 0 0 0 100
Tri a aA_TI 0 0 0 100
Fruit Kiwi
Act d 1 0 0 0.7 99.3
Act d 5 0 0 0 100
Polcalcin
Birch Bet v 4 0 0 0 100
Timothy Phl p 7 0 0 0 100
Grass pollen
Bermuda Cyn d 1 0 1.5 6 92.5
Timothy
Phl p 1 0.7 2.2 0.7 96.3
Phl p 2 0 0.7 0 99.3
Phl p 4 0 0 4.5 95.5
Phl p 5 0.7 1.5 0 97.8
Phl p 6 0 0.7 1.5 97.8
Phl p 11 0 0 2.2 97.8
Tree pollen
Alder Aln g 1 0 0 0.7 99.3
Cedar Cry j 1 0 0 1.5 98.5
Cypress Cup a 1 0 0 3 97
Olive Pollen
Ole e 1 0 0 0 100
Ole e 9 0 0 0 100
Plane Tree Pla a 1 0 0 0 100
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Pla a 2 0 0 1.5 98.5
Weed pollen
Ragweed Amb a 1 0 0 0 100
Mugwort Art v 1 0 0 0 100
Goosefoot Che a 1 0 0.7 0.7 98.5
Wall pellitory Par j 2 0 0 1,5 98.5
Plantain Pla l 1 0 0 0.7 99.3
Saltwort Sal k 1 0 0 0 100
Animals
Cat
Fel d 1 1.5 5.2 0 93.3
Fel d 4 0 2.2 0.7 97
Dog
Can f 1 1.5 2.2 0.7 95.5
Can f 2 0.7 0 0 99.3
Can f 5 0 1.5 0.7 97.8
Horse Equ c 1 0 0.7 0.7 98.5
Mouse Mus m 1 0 1.5 0 98.5
Mould
Alternaria
Alt a 1 0 0.7 0 99.3
Alt a 6 0 0 0.7 99.3
Aspergillus
Asp f 1 0 0 0 100
Asp f 3 0 0.7 0 99.3
Asp f 6 1.5 0.7 0.7 97
Cladosporium Cla h 8 0 0 0 100
Mite
Blomia tropicalis Blo t 5 12.7 39.6 3.7 44
D. farinae
Der f 1 3 33.6 9 54.5
Der f 2 17.9 20.9 2.2 59
D. pteronyssinus
Der p 1 6.7 29.1 6.7 57.5
Der p 2 11.9 23.1 3.7 64.9
Lepidoglyphus destructor Lep d 2 3.7 17.2 8.2 70.9
Insects Cockroach
Bla g 1 0 0 0 100
Bla g 2 0 0 0 100
Bla g 5 0 0 0 100
Venom
Bee
Api m 1 0 0 1.5 98.5
Api m 4 0 0 0.7 99.3
Paper wasp Pol d 5 0 0.7 2.2 97
Common wasp Ves v 5 0 0.7 1.5 98.8
Parasites Anisakis sp. Ani s 1 0 0 0 100
Latex Latex
Hev b 1 0 0.7 0 99.3
Hev b 3 0 0.7 0 99.3
Hev b 5 0 0 0 100
Hev b 6.01 0 0 0.7 99.3
Tropomyosin
Anisakis sp. Ani s 3 0 0.7 1.5 97.8
Cockroach Bla g 7 0 0 1.5 98.5
Mite Der p 10 0 3 3.7 93.3
Shrimp Pen m 1 0 0 0 100
Serum albumin
Cow Bos d 6 0 0 0 100
Dog Can f 3 0 0.7 0 99.3
Horse Equ c 3 0 0 0 100
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Cat Fel d 2 0 0 0 100
nsLTP
Peanut Ara h 9 0 0 0 100
Hazelnut Cor a 8 0 0 0 100
Walnut Jug r 3 0 0.7 0 99.3
Peach Pru p 3 0 0 0 100
Mugwort Art v 3 0 0 0 100
Olive pollen Ole e 7 0 0 0 100
Plane tree Pla a 3 0 0 0 100
PR-10 proteins
Birch Bet v 1 0.7 0.7 0 98.5
Hazel pollen Cor a 1.0101 0 0.7 0.7 98.5
Hazelnut Cor a 1.0401 0 0.7 0.7 98.5
Apple Mal d 1 0 0 0.7 99.3
Peach Pru p 1 0 0 0 100
Soybean Gly m 4 0 0 0 100
Peanut Ara h 8 0 0 0 100
Kiwi Act d 8 0 0 0 100
Celery Api g 1 0 0 0 100
TLP Kiwi Act d 2 0 0 0 100
Profilin
Birch Bet v 2 0 0 0.7 99.3
Latex Hev b 8 0 0.7 2.2 97
Mercury Mer a 1 0 0.7 1.5 97.8
Timothy Phl p 12 0 0 0.7 99.3
CCD Bromelain MUXF 3 0 0.7 0.7 98.5
≥15 ISU, very high ; 1–14.9 ISU, moderate/high; 0.3-0.9 ISU, low; <0.3 ISU negative.
Santosa et al. Clinical and Translational Allergy  (2015) 5:9 Page 7 of 90.55, 95%CI 0.11-0.99, p < 0.001). Tropomyosin levels
were significantly higher in subjects who were sensitized
to HDM and cockroach, but not in those sensitized
to shrimp.
Only one subject out of 60 for whom serum tests for
parasite IgG were conducted had definite immunologic
reactivity to parasite antigen (Toxocara sp) (results not
shown). The subject was atopic with measurable
sensitization to a variety of other tested allergens. The




The number of polysensitized individuals in our cohort
is lower compared to Western populations [13] and
slightly higher than in previously conducted Asian stud-
ies [8,9]. This is possibly due to the inclusion of a large
range of allergens and because we targeted an adult,
symptomatic population.
As shown in previous publications [10,12], HDM is
the dominant allergen in Singapore. Expectedly, co-
sensitization with D. farinae and D. pteronyssinus was
frequent, consistent with evidence of significanthomology between the two allergens [19]. The lower de-
gree of structural similarity between B. tropicalis and
the Dermatophagoides translated to less frequent co-
sensitization between them [20]. It is noteworthy that a
group of symptomatic individuals was monosensitized
to B. tropicalis with both methods (1.1% SPT vs 8%
ISAC). Such information is pertinent in patients
planned for specific immunotherapy, since commer-
cially available HDM immunotherapy kits are largely
targeted against D. farinae and D. pteronyssinus anti-
gens. Immunotherapy kits may need to be individual-
ized to the patients’ sensitization profile.
Only sensitization to HDM was associated with AR. No
allergen was independently associated with asthma or AD,
although this could be due to the smaller number of pa-
tients in each of these groups. Interestingly, although
HDM sensitization on ISAC was documented less fre-
quently than on SPT, it predicted AR in all subjects it iden-
tified, suggesting perhaps that while SPT has better
sensitivity, ISAC may be more specific for clinical symp-
toms. We detected occasional sensitization to a variety of
other allergens but none were associated with symptoms of
atopy. Therefore, in a population with a well-defined dom-
inant allergen, routine clinical screening with a multiplex
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and may in fact introduce the danger of erroneous avoid-
ance of multiple allergens. Careful interpretation of the
data in the context of each patient’s clinical presentation
in warranted.
Shellfish allergies are up to seven times more prevalent
in Asia compared to Western countries, and are the
leading cause of anaphylaxis here [17]. We identified
14.3% of subjects with prawn sensitization on SPT, but
only 1.5% when measured by ISAC. It is difficult to com-
ment if the sensitization on SPT corresponded to clinical
allergy as we did not collect data concerning post-
exposure symptoms. Nevertheless, the agreement be-
tween the two methods for this allergen seemed poor.
We explored whether the disproportionately high fre-
quency of sensitization on SPT was attributable to
cross-reactivity with the ubiquitous HDM tropomyosin
[21,22]. However, sensitization to HDM tropomyosin
(Der p 10) was infrequent, both on ISAC and Immuno-
CAP. In addition, we found little association between
tropomyosin sensitization (as measured by Immuno-
CAP) with shellfish sensitization or, in fact, with HDM
sensitization.
The low rates of sensitization to grass and tree pollen
is known in our tropical environment, where plants are
less reliant on pollination by air. Considering the humid-
ity in our region, we expected a higher frequency of
sensitization to mould. The low allergenic potential of
mould allergens and the complexity of mould allergen
isolation may have contributed to this observation [23].
Further studies are needed to understand mould
sensitization and produce reliable mould antigens for in-
vivo and in-vitro tests.
Comparison between methods & ISAC’s role in Asia
A previous study of Korean patients with AD reported
good correlation between ISAC and SPT. However, only
a narrow range of allergens was included, the population
was small and all subjects were of a single atopic pheno-
type, thus limiting the generalizability of the study’s con-
clusions [24]. In our current study, the agreement
between SPT and ISAC was mostly slight to moderate.
Greatest agreement between the two test methods was
documented with the HDM (κ = 0.64). The agreement
between ISAC and SPT for the remaining allergens was
rather poor, although this analysis was constrained by
the relatively low rates of sensitization to allergens other
than HDM. The low rate of sensitization to the bulk of
the 112 allergens in the ISAC panel underscores the lim-
ited utility of ISAC in Asia. Besides, agreement was sub-
optimal even for the most prevalent allergen.
This is the first Asian study attempting to examine the
applicability of multiplex molecular allergy diagnostic
methods in a mixed group of atopic and non-atopicindividuals. The inclusion of non-atopics improves the
validity of our results. In addition, we collected a large
amount of data to characterize our subjects’ atopic symp-
toms to determine the clinical significance of sensitization.
Nevertheless, there were several limitations. The defini-
tions of atopic phenotypes were based on self-reported
symptoms of disease. However, we attempted to reduce
reporting bias through the use of validated surveys. The
use of questionnaires to characterize exposure based
symptoms would have been helpful to define the clinical
relevance of sensitization to certain allergens such as food
or latex. Future studies with a larger number of patients
and specific exposure based symptoms may help to carve
out a potential role for multiplex assays.
In conclusion, in Asia, the utility of ISAC in its current
make-up is limited by various factors, including differ-
ences in the prevalence of atopy (which may be genetic-
ally determined) and environmental make-up. With its
low cost and rapid turnover, SPTs maintain their central
role in allergy diagnostics. ISAC should not be used as a
screening tool, but has a role in directing immunother-
apy targets and discerning primary from cross reacting
allergens in polysensitized individuals. As locally relevant
allergen species may differ, the allergenic sources in the
test panel should mirror what is locally prevalent, so that
results of the test have improved clinically relevance. It
may be worthwhile to adjust the antigen spectrum on
the ISAC panel to regional differences, in order to in-
crease its applicability locally.Additional file
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